The VanEck Biotech ETF (BBH) provides market-cap-weighted exposure to leading U.S.-listed biotechnology firms.
Icotrokinra met the primary endpoint of clinical response at all three doses, with 36.5% of patients treated achieving endoscopic improvement and 30.2% achieving clinical remission at the highest dose ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback